NCT04572763 2026-01-07
Copanlisib Plus Venetoclax in R/R DLBCL
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
Clinical Trials
8 trialsNCT03711058 2025-09-16
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT04253262 2025-05-04
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Brown University
Phase 1/2 Active not recruiting
NCT04939272 2025-05-01
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT06218667 2024-10-31
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Withdrawn
NCT03877055 2022-12-14
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03052933 2022-06-10
Copanlisib and Gemcitabine in Relapsed/Refractory PTCL
Chonnam National University Hospital
Phase 1/2 Completed
NCT02822482 2021-03-29
COPAN-ORL06
UNICANCER
Phase 1/2 Terminated